Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Alvocidib Potentiates the Activity of Azacytidine in an MCL-1-Dependent Fashion

Wontak Kim, Katherine K. Soh, Jeremiah J. Bearss, Ye Sol Lee, Peter Peterson, PhD, Clifford J. Whatcott, PhD, Adam Siddiqui-Jain, PhD, Steven Weitman, MDPhD, James M Bogenberger, PhD, Raoul Tibes, MD PhD, David J. Bearss, PhD, Steven L. Warner, PhD

Blood (2015) 126 (23): 1343.

https://doi.org/10.1182/blood.V126.23.1343.1343

Published: 2015

Journal Articles

Alvocidib Potentiates the Activity of Cytarabine and Mitoxantrone through the Targeting of MCL-1 When Administered in a Time Sequential Regimen in AML

Wontak Kim, Brigham L. Bahr, Katherine K. Soh, Jeremiah J. Bearss, Ye Sol Lee, Peter Peterson, PhD, Clifford J. Whatcott, PhD, Adam Siddiqui-Jain, PhD, Steven Weitman, MDPhD, David J. Bearss, PhD, Steven L. Warner, PhD

Blood (2015) 126 (23): 3799.

https://doi.org/10.1182/blood.V126.23.3799.3799

Published: 2015

Journal Articles

Inhibition of Axl Kinase Reverses the Mesenchymal Phenotype in Leukemic Cells through the Disruption of Retinoic Acid Signaling

Katherine K. Soh, Brigham L. Bahr, Jeremiah J. Bearss, Wontak Kim, Peter Peterson, PhD, Clifford J. Whatcott, PhD, Adam Siddiqui-Jain, PhD, David J. Bearss, PhD, Steven L. Warner, PhD

Blood (2015) 126 (23): 3253.

https://doi.org/10.1182/blood.V126.23.3253.3253

Published: 2015

Journal Articles

ALK2 Inhibition Via TP-0184 Abrogates Inflammation-Induced Hepcidin Expression and Is a Potential Therapeutic for Anemia of Chronic Disease

Peter Peterson, PhD, Katherine K. Soh, Ye Sol Lee, Wontak Kim, Clifford J. Whatcott, PhD, Adam Siddiqui-Jain, PhD, David J. Bearss, PhD, Steven L. Warner, PhD

Blood (2015) 126 (23): 273.

https://doi.org/10.1182/blood.V126.23.273.273

Published: 2015

Journal Articles

Novel Series of ALK2 Inhibitors That Alter Hepcidin Expression As Potential Therapeutics for Anemia of Chronic Disease

Wontak Kim, Kyle S. Maughan, Katherine K. Soh, Jeremiah J. Bearss, Brigham L. Bahr, David J. Bearss, PhD, Steven L. Warner, PhD

Blood (2014) 124 (21): 212.

https://doi.org/10.1182/blood.V124.21.212.212

Published: 2014

NARROW

Alvocidib Potentiates the Activity of Azacytidine in an MCL-1-Dependent Fashion

Alvocidib Potentiates the Activity of Cytarabine and Mitoxantrone through the Targeting of MCL-1 When Administered in a Time Sequential Regimen in AML

Inhibition of Axl Kinase Reverses the Mesenchymal Phenotype in Leukemic Cells through the Disruption of Retinoic Acid Signaling

ALK2 Inhibition Via TP-0184 Abrogates Inflammation-Induced Hepcidin Expression and Is a Potential Therapeutic for Anemia of Chronic Disease

Novel Series of ALK2 Inhibitors That Alter Hepcidin Expression As Potential Therapeutics for Anemia of Chronic Disease

Email alerts

ASH Publications

American Society of Hematology

Alvocidib Potentiates the Activity of Azacytidine in an MCL-1-Dependent Fashion

Alvocidib Potentiates the Activity of Cytarabine and Mitoxantrone through the Targeting of MCL-1 When Administered in a Time Sequential Regimen in AML

Inhibition of Axl Kinase Reverses the Mesenchymal Phenotype in Leukemic Cells through the Disruption of Retinoic Acid Signaling

ALK2 Inhibition Via TP-0184 Abrogates Inflammation-Induced Hepcidin Expression and Is a Potential Therapeutic for Anemia of Chronic Disease

Novel Series of ALK2 Inhibitors That Alter Hepcidin Expression As Potential Therapeutics for Anemia of Chronic Disease

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only